Latest bid for India’s Fortis “more risky”, says Manipal CEO

India’s privately held Manipal Hospitals had to take a “more risky” approach in its latest bid for domestic rival Fortis Healthcare to see off rival suitors, Manipal’s Chief Executive Ranjan Pai told Reuters.

Manipal on Sunday sweetened its bid for Fortis, offering to inject 21 billion rupees ($312.8 million) to help the ailing hospital operator meet its immediate cash needs, a move that Pai said was risky because Fortis is embroiled in a regulatory investigation that is clouding its prospects.

In its previous bid Manipal and consortium partner TPG Capital had proposed to take over Fortis at the same valuation of 160 rupees a share, or a total valuation of 83.58 billion rupees ($1.24 billion), without offering any initial cash injection.

“Yes, this is a more risky structure … because we don’t know what’s going to come out of the SFIO,” Pai said on Monday, referring to India’s Serious Fraud Investigation Office.

The SFIO is investigating allegations that Fortis founders Malvinder Singh and Shivinder Singh took funds from the company. The duo, who have since left the company, deny wrongdoing.

In March Fortis said it was looking into the allegations and that it expected the SFIO investigation to end in less than a year.

Fortis has been a target of five firms and investment groups vying for control of its 30-odd hospitals across India. Among them is Malaysia’s IHH Healthcare, which wants to invest as much as 40 billion rupees at 175 rupees a share, higher than the share price offered by Manipal.

TRACK RECORD
Manipal did not want to be “irrational” in its bid, Pai said, adding that it brought a lot of value to Fortis and its investors with its experience in running hospitals and track record of providing good exit for private equity players.

“I think, beyond price, people have to look at what is good for the company in the medium to long term,” he said, adding that Manipal did not want to enter at a very high price and disappoint investors later if the share price falls.

Indian businessmen Sunil Munjal and Anand Burman have also offered to buy a stake in Fortis at 167 rupees a share as part of their offer totalling 18 billion rupees.

Radiant Life Care, backed by private equity firm KKR & Co and China’s Fosun International, are the other Fortis suitors.

Pai said he did not expect the deal to face antitrust hurdles because the combined company’s market share will be in “single digits” and a merger should take six to nine months to complete.

If a deal goes through, TPG will own about 14 percent the new Fortis, while Manipal’s founder company and other investors will together own 35.4 percent.

Pai said that Manipal has held talks with many of the long-term and major investors at Fortis.

“We want to assure them that if we are given control of the company, corporate governance levels and transparency will be at the highest.”

  • Related Posts

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    AiMeD welcomes the move long overdue to boost India’s Regulatory Framework New Delhi: 21 Drug Inspectors have been promoted to Assistant Drugs Controllers (India) under CDSCO. It was long unmet…

    Yashoda Medicity lifts Benchmark in Critical Care to New High

    With the introduction of North India’s first Advanced VitalGo Total Lift Bed Technology Ghaziabad/ New Delhi: In an ideal hospital, critical care is most paramount and it is also the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    NHS backs delayed‑release treatment for cystinosis

    NHS backs delayed‑release treatment for cystinosis

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

    Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

    Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

    Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

    Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

    Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

    AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care

    AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care